- Home
- UBXG vs AVTX Comparison
UBXG vs AVTX Comparison
Compare UBXG & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBXG
- AVTX
- Stock Information
- Founded
- UBXG 2018
- AVTX 2011
- Country
- UBXG China
- AVTX United States
- Employees
- UBXG N/A
- AVTX N/A
- Industry
- UBXG
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- UBXG
- AVTX Health Care
- Exchange
- UBXG Nasdaq
- AVTX Nasdaq
- Market Cap
- UBXG 67.8M
- AVTX 57.4M
- IPO Year
- UBXG 2024
- AVTX 2015
- Fundamental
- Price
- UBXG $2.94
- AVTX $7.89
- Analyst Decision
- UBXG
- AVTX Strong Buy
- Analyst Count
- UBXG 0
- AVTX 7
- Target Price
- UBXG N/A
- AVTX $31.00
- AVG Volume (30 Days)
- UBXG 18.5K
- AVTX 149.3K
- Earning Date
- UBXG 01-01-0001
- AVTX 08-11-2025
- Dividend Yield
- UBXG N/A
- AVTX N/A
- EPS Growth
- UBXG N/A
- AVTX N/A
- EPS
- UBXG N/A
- AVTX N/A
- Revenue
- UBXG $39,603,353.00
- AVTX $441,000.00
- Revenue This Year
- UBXG N/A
- AVTX N/A
- Revenue Next Year
- UBXG N/A
- AVTX N/A
- P/E Ratio
- UBXG N/A
- AVTX $1.17
- Revenue Growth
- UBXG N/A
- AVTX N/A
- 52 Week Low
- UBXG $2.36
- AVTX $3.39
- 52 Week High
- UBXG $567.04
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- UBXG N/A
- AVTX 80.64
- Support Level
- UBXG N/A
- AVTX $6.21
- Resistance Level
- UBXG N/A
- AVTX $6.89
- Average True Range (ATR)
- UBXG 0.00
- AVTX 0.64
- MACD
- UBXG 0.00
- AVTX 0.17
- Stochastic Oscillator
- UBXG 0.00
- AVTX 78.59
About UBXG U-BX Technology Ltd. Ordinary Shares
U-BX Technology Ltd is focused on providing value-added services using artificial intelligence-driven technology to businesses within the insurance industry, including insurance carriers and brokers. It helps institutional clients obtain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or its clients' promotion time through those channels. The company derives a majority of its revenue by providing digital promotion services to its clients and also engages in providing risk assessment services, and value-added bundled benefits. It has developed an algorithm named Magic Mirror, to calculate payout risks for insurance carriers to underwrite auto insurance coverage. Geographically, all of the company's revenue is derived from Mainland China.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).